Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
Rhea-AI Summary
Edgewise Therapeutics (Nasdaq: EWTX) announced that its CIRRUS-HCM Phase 2 trial abstract, featuring 12-week top-line data for cardiac sarcomere modulator EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy, has been selected as a late-breaking science presentation at the ESC Congress 2026 in Munich.
The talk, presented by Anjali Tiku Owens, M.D., is scheduled for Monday, August 31, 2026, 11:30–11:45 am CEST in the session “Transforming the heart: novel therapies for myocardial disease and heart failure,” located in Achgabat (Hall A3). The presentation will be posted on the Edgewise website after delivery.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 06 | Q2 earnings report | Positive | -1.3% | Reported cash resources, Servier transaction proceeds, and cardiovascular pipeline refocus. |
| Jul 13 | Business acquisition | Positive | -9.1% | Servier completed acquisition of Edgewise's muscular dystrophy business. |
| Jul 13 | Business sale | Positive | -9.1% | Edgewise completed the sevasemten sale and refocused on cardiovascular development. |
| Jul 01 | Inducement grants | Negative | -3.6% | The company granted inducement stock options covering 16,500 shares. |
| Jun 16 | Phase 2 clinical data | Positive | -3.6% | Positive CIRRUS-HCM data supported planned Phase 3 initiation. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Four of five recent news events were followed by price reactions opposite to the event sentiment classification.
Key Terms
hypertrophic cardiomyopathy medical
cardiac sarcomere modulator medical
systolic function medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –
Late-Breaking Science Presentation:
Presenter: Anjali Tiku Owens, M.D., Associate Professor of Medicine in the Division of Cardiology at the Perelman School of Medicine of the University of
Date: Monday, August 31, 2026, 11:30 – 11:45 am CEST
Session: Transforming the heart: novel therapies for myocardial disease and heart failure
Location: Achgabat (Hall A3)
The presentation will be available on the Edgewise website after it is presented.
About CIRRUS-HCM
CIRRUS-HCM is a multi-part, open label trial of EDG-7500 in participants with obstructive and nonobstructive HCM at over 20 clinical sites in the
About Hypertrophic Cardiomyopathy
HCM is the most common form of genetic heart disease, affecting approximately one in 500 people, and is associated with reduced quality of life and an elevated risk of heart failure, abnormal heart rhythms, and sudden cardiac death. Individuals with HCM can become extremely limited in their functional capacity and ability to perform the activities of daily living. Commonly experienced symptoms include breathlessness, irregular heartbeat, chest pain, tiredness, dizziness, or even fainting. These symptoms are caused by excessive contraction and thickening (hypertrophy) of the left ventricular wall of the heart. Over time, the thickened muscle becomes stiff, making it difficult for the heart to relax and fill with blood (diastolic dysfunction). There are two major forms of HCM: obstructive and nonobstructive. Despite advancements in treatment options for some patients with HCM, there remains a significant unmet need for additional therapeutic approaches for patients.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading biopharmaceutical company focused on developing innovative therapies for serious cardiovascular and cardiometabolic diseases. Leveraging its expertise in integrated muscle physiology and small molecule drug development, Edgewise is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy and heart failure. To learn more, go to edgewisetx.com or follow Edgewise on LinkedIn, X, Facebook and Instagram.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-announces-upcoming-late-breaking-science-presentation-at-the-european-society-of-cardiology-esc-congress-2026-302857842.html
SOURCE Edgewise Therapeutics